Genomes and Genes
interleukin 6 receptors
Summary: Receptors present on T cells, mitogen-activated B cells, peripheral monocytes, and some macrophage- and B cell-derived tumor cell types. The receptor is a strongly glycosylated protein of 80 kDa and a length of 468 amino acids. (Ibelgaufts, Dictionary of Cytokines, 1995)
Publications249 found, 100 shown here
- Interleukin-6 and its receptor in cancer: implications for translational therapeuticsDavid S Hong
Phase I Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 110:1911-28. 2007..Therapeutic targeting of IL-6 and its receptor in cancer has strong biologic rationale, and there is preliminary evidence suggesting that targeting of the IL-6 system may be beneficial in the treatment of cancer...
- Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammationS M Hurst
Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3US, Wales, United Kingdom
Immunity 14:705-14. 2001....
- IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammationGilles Kaplanski
INSERM U387, Hopital Sainte Marguerite, 270 Boulevard de Sainte Marguerite, 13009 Marseille, France
Trends Immunol 24:25-9. 2003..Furthermore, we suggest that the first Toll-like family receptors that arose in evolution might have acted in both development and immunity by recognizing the degradation of endogenous macromolecules...
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialP Emery
Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UK
Ann Rheum Dis 67:1516-23. 2008..The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy...
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug theMark C Genovese
Division of Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
Arthritis Rheum 58:2968-80. 2008..To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with conventional disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis (RA)...
- The soluble interleukin 6 receptor: mechanisms of production and implications in diseaseS A Jones
Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3US, Wales, UK
FASEB J 15:43-58. 2001..We want to convey, therefore, that when thinking about the inflammatory capability of IL-6, it is essential to consider not only the action of IL-6 itself, but also the effect sIL-6R may have on cellular processes...
- Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130T Taga
Division of Immunology, Osaka University, Japan
Cell 58:573-81. 1989..These findings indicate that the complex of IL-6 and IL-6-R can interact with a non-ligand-binding membrane glycoprotein, gp130, extracellularly and can provide the IL-6 signal...
- Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancerStefan Rose-John
Biochemisches Institut, Christian Albrechts Universitat zu Kiel, Olshausenstr 40, D 24098 Kiel, Germany
J Leukoc Biol 80:227-36. 2006..The pathophysiological mechanisms by which the IL-6/sIL-6R complex regulates the inflammatory state are discussed...
- Interleukin-6 and its receptor: from bench to bedsideJürgen Scheller
Institut fur Biochemie, Christian Albrechts Universitat zu Kiel, Olshausenstr 40, 24098 Kiel, Germany
Med Microbiol Immunol 195:173-83. 2006..These designer cytokines have been shown to be extremely useful to in therapeutic applications ranging from the long-term culture of stem cells and enhancing liver regeneration up to the blockade of chronic inflammation and cancer...
- Principles of interleukin (IL)-6-type cytokine signalling and its regulationPeter C Heinrich
Institut fur Biochemie, RWTH Aachen, Universitatsklinikum, Pauwelsstrasse 30, D 52074 Aachen, Germany
Biochem J 374:1-20. 2003..Also the cross-talk between the JAK/STAT pathway with other signalling cascades is discussed...
- Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateR N Maini
Kennedy Institute of Rheumatology Division, Imperial College, London, UK
Arthritis Rheum 54:2817-29. 2006....
- Inhibition of IL-6 for the treatment of inflammatory diseasesNorihiro Nishimoto
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita City, Osaka, 565 0871, Japan
Curr Opin Pharmacol 4:386-91. 2004..Humanized anti-IL-6 receptor antibody has been developed as a therapeutic agent for these diseases, and therapeutic benefits have been revealed in clinical studies...
- Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapyN Nishimoto
Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Suita City, Osaka, Japan
Blood 95:56-61. 2000..Blood. 2000;95:56-61)..
- Anti-interleukin 6 receptor antibody treatment in rheumatic diseaseN Nishimoto
Department of Medical Science I, School of Health and Sport Sciences, Osaka University, 2 1 Yamada oka, Suita City, Osaka 565 0871, Japan
Ann Rheum Dis 59:i21-7. 2000..In this review, the new therapeutic strategy for Castleman's disease and RA using humanized antibody to human IL6 receptor, MRA, is discussed...
- Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophilsAthena Chalaris
Department of Biochemistry, Christian Albrechts University, Kiel, Germany
Blood 110:1748-55. 2007....
- Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptorKamilla Malinowska
Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
Endocr Relat Cancer 16:155-69. 2009..Taken together, data in the present study demonstrate that IL-6 may cause growth of androgen receptor-positive tumours in vitro and in vivo through activation of the androgen receptor...
- Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasisS F Shariat
Baylor Prostate Center, Scott Department of Urology, Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
Urology 58:1008-15. 2001....
- Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman diseaseNorihiro Nishimoto
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1 3 Yamada oka, Suita, Osaka 565 0871, Japan
Blood 106:2627-32. 2005..Most adverse events were mild to moderate in severity. MRA was tolerated well and significantly alleviated chronic inflammatory symptoms and wasting in patients with MCD...
- Characterization of the role of IL-6 in the progression of prostate cancerT D Chung
Department of Radiation and Cellular Oncology, University of Chicago, Illinois, USA
Prostate 38:199-207. 1999..In the present study, we investigated the expression of members of the IL-6 supergene family and related cytokines and the potential role of IL-6 in prostate cancer growth regulation...
- JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expressionFlorence Legendre
Laboratoire de Biochimie du Tissu Conjonctif, Faculte de Medecine, 14032 Caen Cedex, France
J Biol Chem 278:2903-12. 2003..These IL-6 effects might contribute to the phenotype loss of chondrocytes in joint diseases and the alteration of articular cartilage associated with this pathology...
- Interleukin-6 is a growth factor for nonmalignant human plasmablastsG Jego
, Institut de Biologie, Nantes, France
Blood 97:1817-22. 2001..Finally, IL-6 enhanced the proliferation (2-fold increase) of IL-2-generated plasmablasts. In conclusion, the data indicate that IL-6 is a growth factor for nonmalignant human plasmablasts...
- Characterization of anti-mouse interleukin-6 receptor antibodyMakoto Okazaki
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd, 135 Komakado 1 chome, Gotemba shi, Shizuoka 412 8513, Japan
Immunol Lett 84:231-40. 2002..These lines of evidence demonstrate that MR16-1 is useful to investigate the physiological and pathological roles of IL-6 and sIL-6R in mice...
- The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancerMichael W Kattan
Scott Department of Urology, Baylor College of Medicine, 6535 Fannin St, Houston, TX 77030, USA
J Clin Oncol 21:3573-9. 2003....
- Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivoR Atreya
Lab of Immunology and Section Pathophysiology, I Medical Clinic, University of Mainz, 55131 Mainz, Germany
Nat Med 6:583-8. 2000..These data indicate that a pathway of T-cell activation driven by IL-6-sIL-6R contributes to the perpetuation of chronic intestinal inflammation. Specific targeting of this pathway may be a promising new approach for the treatment of CD...
- Molecular cloning and expression of an IL-6 signal transducer, gp130M Hibi
Division of Immunology, Osaka University, Japan
Cell 63:1149-57. 1990..A cloned gp130 could associate with a complex of IL-6 and soluble IL-6-R and transduce the growth signal when expressed in a murine IL-3-dependent cell line...
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition tNorihiro Nishimoto
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
Mod Rheumatol 19:12-9. 2009..All serious adverse events improved by adequate treatment. Tocilizumab monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX...
- The paradigm of IL-6: from basic science to medicineTetsuji Naka
Department of Molecular Medicine, Osaka University Graduate School of Medicine, Japan
Arthritis Res 4:S233-42. 2002..On the basis of the findings, a new therapeutic approach to block the IL-6 signal using humanized anti-IL-6R antibody for rheumatoid arthritis, Castleman's disease, and multiple myeloma has been attempted...
- Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastomaRachel A Egler
Department of Pediatrics, Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 14:7028-34. 2008..To explore the relationships between interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) levels and disease extent and clinical outcome in childhood neuroblastoma...
- Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whitesYasmin H Hamid
Steno Diabetes Center, Hagedorn Research Institute, Gentofte, Copenhagen, Denmark
Diabetes 53:3342-5. 2004..In conclusion, the Asp358Ala polymorphism of the IL6R associates with type 2 diabetes in Danish whites...
- 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signalingW Somers
Small Molecule Drug Discovery, Genetics Institute, Inc, Cambridge, MA 02140, USA
EMBO J 16:989-97. 1997..Based on this model, we predict a fourth binding site on IL-6, a low affinity IL-6-IL-6 interaction, which may be necessary for the sequential assembly of a functional hexameric IL-6 receptor complex...
- In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonistF De Benedetti
Dipartimento di Scienze Pediatriche, Instituto di Ricerca e Cura a Carattere Scientifico Policlinico San Matteo, Universita' degli Studi di Pavia, Pavia, Italy
J Immunol 166:4334-40. 2001..Immunization with Sant1 could therefore represent a novel and simple therapeutic approach for the specific neutralization of IL-6 in humans...
- The IL-6/sIL-6R complex as a novel target for therapeutic approachesStefan Rose-John
Biochemisches Institut, Christian Albrechts Universitat zu Kiel, Kiel, Germany
Expert Opin Ther Targets 11:613-24. 2007..An optimised variant of the recently described fusion protein sgp30Fc is now heading towards its clinical evaluation...
- IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariaePy Palmqvist
Department of Oral Cell Biology, Umea University, Umea, Sweden
J Immunol 169:3353-62. 2002....
- Interleukin 6 and its receptor: ten years laterT Hirano
Department of Molecular Oncology, Osaka University Medical School, Japan
Int Rev Immunol 16:249-84. 1998..The deregulated expression of IL-6 and its receptor is involved in a variety of diseases...
- Technology evaluation: MRA, ChugaiChanghai Ding
Menzies Centre for Population Health Research, University of Tasmania, 17 Liverpool Street, Hobart, 7000 TAS, Australia
Curr Opin Mol Ther 5:64-9. 2003..MRA is currently undergoing phase II clinical trials for these indications...
- Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cellsL Snyers
Department of Virology, Institut Pasteur du Brabant, Brussels, Belgium
Proc Natl Acad Sci U S A 87:2838-42. 1990....
- Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?Reinhard E Voll
Department of Internal Medicine III, Friedrich Alexander University of Erlangen Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
Ann N Y Acad Sci 1051:799-810. 2005....
- Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trialShumpei Yokota
Department of Paediatrics, Yokohama City University School of Medicine, Yokohama, Japan
Lancet 371:998-1006. 2008..We investigated the efficacy and safety of tocilizumab, an anti-interleukin-6-receptor monoclonal antibody, in children with this disorder...
- TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signalingChristoph Becker
Laboratory of Immunology, I Medical Clinic, University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
Immunity 21:491-501. 2004..Taken together, our data provide novel insights into TGF-beta signaling in colorectal cancer and suggest novel therapeutic approaches for colorectal cancer based on inhibition of TGF-beta-dependent IL-6 trans-signaling...
- Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical studyNorihiro Nishimoto
Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Suita City, Japan
J Rheumatol 30:1426-35. 2003..To evaluate the safety and pharmacokinetics of multiple infusions of a humanized anti-interleukin-6 (IL-6) receptor antibody, MRA, in patients with rheumatoid arthritis (RA)...
- Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitmentM Romano
Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy
Immunity 6:315-25. 1997..Hence, in vivo and in vitro evidence supports the concept that the IL-6 system plays an unexpected positive role in local inflammatory reactions by amplifying leukocyte recruitment...
- Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptorK Yamasaki
Division of Immunology, Osaka University, Japan
Science 241:825-8. 1988..The cytoplasmic domain of approximately 82 amino acids lacks a tyrosine/kinase domain, unlike other growth factor receptors...
- Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritisHideko Nakahara
Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Osaka, Japan
Arthritis Rheum 48:1521-9. 2003..To investigate whether interleukin-6 (IL-6) is a regulator of vascular endothelial growth factor (VEGF) in rheumatoid arthritis (RA)...
- IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinaseM Murakami
Institute for Molecular and Cellular Biology, Osaka University, Japan
Science 260:1808-10. 1993..Thus, a general first step in IL-6-related cytokine signaling may be the dimerization of signal-transducing molecules and activation of associated tyrosine kinases...
- Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6T Tamura
Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
Proc Natl Acad Sci U S A 90:11924-8. 1993..This may play an important physiological or pathological role in conditions associated with increased osteoclastic bone resorption...
- Interleukin-6 trans-signalling in chronic inflammation and cancerJ Scheller
Biochemisches Institut, Christian Albrechts Universitat zu Kiel, Kiel, Germany
Scand J Immunol 63:321-9. 2006..The pathophysiologic mechanisms by which the IL-6/soluble IL-6R complex perpetuates the inflammatory state are discussed...
- Palmitate-induced interleukin-6 expression in human coronary artery endothelial cellsHarald Staiger
Department of Endocrinology, Metabolism and Pathobiochemistry, Medical Clinic, Eberhard Karls University, Tubingen, Germany
Diabetes 53:3209-16. 2004..29, P < 0.05). We show here that the common plasma FFA palmitate induces high levels of IL-6 in CAECs. Furthermore, palmitate correlates with IL-6 in vivo. This points to a potential contribution of palmitate to vascular inflammation...
- IL-6 signal transduction and its physiological roles: the signal orchestration modelD Kamimura
Department of Molecular Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Rev Physiol Biochem Pharmacol 149:1-38. 2003....
- Signaling mechanisms through gp130: a model of the cytokine systemT Hirano
Department of Oncology, Biomedical Research Center, Osaka University Medical School, Suita, Japan
Cytokine Growth Factor Rev 8:241-52. 1997....
- Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trialNorihiro Nishimoto
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Suita City, Osaka, Japan
Arthritis Rheum 50:1761-9. 2004..This study was undertaken to evaluate the safety and efficacy of a humanized anti-IL-6 receptor antibody, MRA, in patients with RA...
- Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeysM Mihara
Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Shizuoka, Japan
Clin Immunol 98:319-26. 2001..Our results demonstrate that IL-6 plays an important role in monkey CIA and that MRA may be an attractive agent for the treatment of rheumatoid arthritis...
- A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's diseaseHiroaki Ito
Department of Molecular Medicine, Graduate School of Medicine, Osaka University, Suita
Gastroenterology 126:989-96; discussion 947. 2004..We carried out a pilot placebo-controlled study to investigate the efficacy, pharmacokinetics, and safety of MRA, a humanized monoclonal antibody to IL-6 receptor, in patients with active Crohn's disease...
- Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanismS Horiuchi
Department of Microbiology, Faculty of Medicine, Tokyo Medical and Dental University, Japan
Eur J Immunol 24:1945-8. 1994..Our results indicate that active deletion of the TM domain by alternative splicing of mRNA represents one mechanism for release of sIL-6R into the culture supernatants of cells, or into serum or urine...
- Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130M Narazaki
Division of Immunology, Osaka University, Japan
Blood 82:1120-6. 1993..Recombinant sgp130 showed inhibitory effect on the biologic function of such cytokines. This work implies physiologic roles of naturally produced serum sgp130 in modulating signals through gp130...
- IL-6 transsignaling: the in vivo consequencesSimon A Jones
Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3US, Wales, UK
J Interferon Cytokine Res 25:241-53. 2005..The mechanism by which the IL-6/sIL-6R complex regulates the inflammatory or neoplastic state is discussed...
- Interleukin-6 receptor gene variations, plasma interleukin-6 levels, and type 2 diabetes in U.S. WomenLu Qi
Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
Diabetes 56:3075-81. 2007..To examine the associations between common variations in the IL6R gene and circulating interleukin (IL)-6 levels and diabetes risk...
- Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivityHua Wang
Division of Endocrinology and Metabolism, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
J Clin Endocrinol Metab 90:1123-9. 2005..IL-6R is not likely to explain the linkage to diabetes in this region, but our work supports a minor role of variants in T2DM risk and suggests that sequence variants may alter IL-6R mRNA levels and possibly levels of soluble IL-6R...
- IL-6 signaling promotes tumor growth in colorectal cancerC Becker
Lab of Immunology, I Medical Clinic, University of Mainz, Mainz, Germany
Cell Cycle 4:217-20. 2005..In summary, our data provide novel insights into the role of TGF-beta signaling in colorectal cancer and suggest novel therapeutic approaches for colorectal cancer based on an inhibition of TGF-beta-dependent IL-6 trans-signaling...
- Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patientsE Kovacs
Society for Cancer Research, Arlesheim, Switzerland
Biomed Pharmacother 55:391-6. 2001..This is the first report to investigate sgp130 in cancer patients with different types of tumour...
- Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritisSusyn L Plushner
Clinical Pharmacy Specialist in Rheumatology and Therapeutic Initiatives, 2045 Franklin St, Denver, CO 80205, USA
Ann Pharmacother 42:1660-8. 2008..To review the pharmacology, pharmacokinetics, clinical trial data, and safety profile of tocilizumab, a new biologic agent targeting the interleukin-6 cytokine receptor...
- Interleukin-6 receptor gene, plasma C-reactive protein, and diabetes risk in womenLu Qi
Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
Diabetes 58:275-8. 2009..Because IL6R variants were previously associated with IL-6 levels, we tested whether the associations with CRP were independent of IL-6 and the interactions between IL6R variants and CRP in relation to diabetes risk...
- Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levelsDavid Reich
Department of Genetics, Harvard Medical School, New Research Building, Boston, MA 02115, USA
Am J Hum Genet 80:716-26. 2007..0x10-12 for IL-6 SR, and P<2.0x10-9 for IL-6. These results also serve as an important proof of principle, showing that admixture mapping can not only coarsely localize but can also fine map a phenotypically important variant...
- Induction of neuronal and myelin-related gene expression by IL-6-receptor/IL-6: a study on embryonic dorsal root ganglia cells and isolated Schwann cellsPei Lin Zhang
Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
Exp Neurol 208:285-96. 2007..On the contrary, we observed that IL6RIL6 inhibited the genes related to TGF-beta family as well as the production of smooth muscle actin...
- Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibodyJ Ogawa
Ann Rheum Dis 65:1667-9. 2006
- sIL-6R: more than an agonist?Heike Knüpfer
Institute of Clinical Pharmacology, University of Leipzig, Härtelstrasse 16 18, Leipzig, Germany
Immunol Cell Biol 86:87-91. 2008..Knowledge about additional properties of sIL-6R will enlarge the biologic understanding of this molecule and might give an explanation for the sometimes contrasting effects of the cytokine IL-6...
- The role of transsignalling via the agonistic soluble IL-6 receptor in human diseasesKarl Josef Kallen
Biochemisches Institut, Christian Albrechts Universitat zu Kiel, Germany
Biochim Biophys Acta 1592:323-43. 2002..A specific treatment option for diseases influenced by the sIL-6R could be based on gp130-Fc, a soluble gp130 (sgp130) linked to the Fc-fragment of IgG1. gp130-Fc has shown efficacy in vivo in animal models of Crohn's disease...
- The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosisYadav Wagley
Department of Anatomy, College of Medicine, Chosun University, 375 Seosuk dong, Dong Gu, Gwangju, Republic of Korea
Biochem Biophys Res Commun 354:985-91. 2007..These results suggest that the IL6/sIL6R/gp130 system, which sensitizes TNF-alpha-resistant melanoma cells to TNF-alpha-induced apoptosis, may provide a new target for immunotherapy...
- Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130Mari A Nowell
Cardiff School of Biosciences, Cardiff University, Cardiff, Wales, United Kingdom
J Immunol 171:3202-9. 2003..Specific blockade of soluble IL-6R signaling in wild-type mice using soluble gp130 ameliorated disease. Consequently, soluble IL-6R-mediated signaling represents a promising therapeutic target for the treatment of rheumatoid arthritis...
- Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritisShumpei Yokota
Yokohama City University School of Medicine, Kanagawa, Japan
Arthritis Rheum 52:818-25. 2005....
- Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cellsKeon Wook Kang
College of Pharmacy, Chosun University, Gwangju 501 759, Korea
Free Radic Biol Med 42:215-27. 2007..These results suggest that IL-6/sIL-6R/gp130 complex signaling has an unexpected positive effect on iNOS gene expression through JNK/p38 MAPK mediated-AP-1 activation in melanoma cells...
- Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cellsTakeharu Kanazawa
Department of Otolaryngology, Jichi Medical University, Omiya Medical Center, 857 1 Amanuma, Omiya Saitama City, Saitama, 330 8503, Japan
Eur Arch Otorhinolaryngol 264:815-21. 2007..These results suggest that IL-6 can directly influence cell proliferation and the invasion potential as the first step of tumor metastasis...
- Interleukin-6 trans-signaling in inflammatory bowel diseaseKeiichi Mitsuyama
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Asahi machi 67, Kurume 830 0011, Japan
Cytokine Growth Factor Rev 17:451-61. 2006..These studies suggest that IL-6 trans-signaling may play a role in the development of IBD; they therefore imply the possibility of a selective therapeutic strategy to target this signaling...
- Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell lineHirofumi Nakanishi
Department of Biology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka 537 8511, Japan
Am J Pathol 165:471-80. 2004....
- Interleukin-6: discovery of a pleiotropic cytokineTadamitsu Kishimoto
Laboratory of Immunoregulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan
Arthritis Res Ther 8:S2. 2006..When taking into account all the accumulated basic research on the various aspects of this molecule, it appeared that blocking the activity of IL-6 was a feasible, new therapeutic approach for chronic inflammatory diseases...
- The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cellsS Ozbek
Department of Medicine, Section of Pathophysiology, University of Mainz, Obere Zahlbacher Strasse 63, D-55101 Mainz, Germany
Oncogene 20:972-9. 2001..These results demonstrate that the anti-tumor effect of cytokines like IL-6 which are secreted by transfected melanoma cells at least in part depends on GM-CSF activity...
- Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changesN Giuliani
Dipartimento di Medicina Interna e Scienze Biomediche, , Via Gramsci 14, 43100, Parma, Italy
Exp Gerontol 36:547-57. 2001....
- IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilageC R Flannery
Connective Tissue Biology Research Group, Cardiff School of Biosciences, Cardiff University, Museum Avenue, CF10 3US, Cardiff, UK
Matrix Biol 19:549-53. 2000..This catabolism was associated with aggrecanase (but not MMP) activity, with correlative mRNA expression for aggrecanase-2...
- Effects of IL-6 and its soluble receptor on proteoglycan synthesis and NO release by human articular chondrocytes: comparison with IL-1. Modulation by dexamethasoneP A Guerne
Division of Rheumatology, Hopital Cantonal Universitaire, Geneva, Switzerland
Matrix Biol 18:253-60. 1999..In conclusion, sIL-6Ralpha potentiates the inhibitory effect of IL-6 on PG synthesis by articular chondrocytes, but the overall effect of IL-6 + IL-6sR is moderate compared to the effects of IL-1...
- IL-6 as an intracrine growth factor for renal carcinoma cell linesLaurent Alberti
Equipe Cytokine et Cancer, Unité Inserm 590, Lyon, France
Int J Cancer 111:653-61. 2004..IL-6 ASON inhibited the proliferation of the 8 RCC cell lines tested additively with IL-4 or IL-13. IL-6 is an intracrine growth factor in renal cell carcinoma cell lines...
- Increased levels of plasma interleukin-6 soluble receptor in patients with essential thrombocythemiaRosana Marta
Sección Hematología Investigación, Instituto de Investigaciones Medicas Alfredo Lanari, Facultad de Medicina, Universidad de Buenos Aires, Argentina
Haematologica 89:657-63. 2004..We also evaluated IL-6R on leukocyte membrane and IL-6R/IL-6sR mRNA expression in mononuclear cells...
- Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritisShumpei Yokota
Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
Clin Rev Allergy Immunol 28:231-8. 2005..A confirmation of the role of tocilizumab in the treatment of sJIA will be provided by the results of the ongoing phase III study in Japan...
- The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombinV Marin
, , and Immunotech, a Beckman Coulter Company, Marseille, France
J Immunol 167:3435-42. 2001..sIL-6Ralpha may then complex with IL-6 and increase the amount of MCP-1 produced by thrombin-activated endothelium, favoring monocyte infiltration, and the transformation of acute into chronic inflammation...
- Functional murine interleukin 6 receptor with the intracisternal A particle gene product at its cytoplasmic domain. Its possible role in plasmacytomagenesisT Sugita
Institute for Molecular and Cellular Biology, Osaka University, Japan
J Exp Med 171:2001-9. 1990..Since IL-6 functions as a potent growth factor for murine plasmacytomas, over-expression of abnormal IL-6-R may function as a positive selection element for the development of certain plasmacytomas...
- IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture systemMisato Hashizume
Product Research Department, Chugai Pharmaceutical Co, Ltd, Gotemba, Shizuoka 412 8513, Japan
Rheumatol Int 29:1449-54. 2009..In conclusion, IL-6/sIL-6R complex showed angiogenic activity via the production of VEGF from RA-FLS, but TNF-alpha was anti-angiogenic in our experimental system...
- CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130N Y Ip
Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591
Cell 69:1121-32. 1992..Thus, the receptor system for CNTF is surprisingly unlike those used by the nerve growth factor family of neurotrophic factors, but is instead related to those used by a subclass of hematopoietic cytokines...
- Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAsStephan W Lindemann
Program in Human Molecular Biology and Genetics, University of Utah, 15 North, 20230 East, Building 533, Room 4220, Salt Lake City, UT 84112, USA
Proc Natl Acad Sci U S A 101:7076-81. 2004..Signal-dependent translation in activated neutrophils may be a critical mechanism for alteration of the inflammatory milieu and a therapeutic target...
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseNorihiro Nishimoto
Laboratory of Immune Regulation, Graduate School of Frontier Bioscience, Osaka University, Osaka, Japan
Blood 112:3959-64. 2008..We also concluded that the increased level of free IL-6 during tocilizumab treatment closely reflects the actual endogenous IL-6 production and true disease activity...
- [Interleukin-6 in pathogenesis of rheumatoid arthritis]Masahiko Mihara
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co Ltd
Nihon Rinsho 63:158-62. 2005
- Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neuronsO Obreja
Institut fur Physiologie und Experimentelle Pathophysiologie, Friedrich Alexander Universitat, Erlangen Nurnberg, Germany
Brain 128:1634-41. 2005..Together, the results suggest that IL-6-sIL-6R acts directly on sensory neurons. It increases their susceptibility to noxious heat via the gp130/Jak/PKCdelta signalling pathway...
- Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stressQing Chen
Department of Immunology, Roswell Park Cancer Institute, Carlton and Elm Streets, Buffalo, NY 14263, USA
Immunity 20:59-70. 2004..These results highlight a role for gp130-linked IL-6/sIL-6Ralpha transsignaling in amplifying lymphocyte trafficking during febrile inflammatory responses...
- TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complexJohannes G Bode
Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Medizinische Klinik der Heinrich Heine Universität, Dusseldorf, Germany
J Immunol 171:257-66. 2003..Furthermore, activation of p38 mitogen-activated protein kinase is shown to be essential for the inhibitory effect of TNF-alpha on IL-6 signaling and TNF-alpha-dependent recruitment of SHP2 to gp130...
- Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptorGeorgios Skiniotis
Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA
Nat Struct Mol Biol 12:545-51. 2005..Variation in the receptor bend angles suggests a possible conformational transition from open to closed states upon ligand binding; this transition is probably representative of the other tall cytokine receptors...
- Bow to your partner for signalingHeike M Hermanns
Nat Struct Mol Biol 12:476-8. 2005
- Norepinephrine-induced interleukin-6 increase in rat hearts: differential signal transduction in myocytes and non-myocytesW Briest
Carl Ludwig Institute of Physiology, University of Leipzig, Liebigstrasse 27, 04103 Leipzig, Germany
Pflugers Arch 446:437-46. 2003..In contrast, the IL6R protein and the downstream regulator STAT3 were increased only in MCs after 24 h of NE infusion. The mRNA of C/EBP-delta, which is regulated by STAT3, was elevated only in myocytes...
- In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRDBruno Memoli
Department of Nephrology, University Federico II of Naples, Via Tasso 91 B, Napoli 80127, Italy
J Am Soc Nephrol 16:1099-107. 2005..This release is seemingly due to a shedding of membrane-bound gp130 receptor. The increased sgp130 release may partially counteract the inflammatory effects caused by IL-6...
- Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulationCecile Ancey
Laboratoire des Biomembranes et Signalisation Cellulaire, UMR CNRS 6558, Universite de Poitiers, 40 Avenue du Recteur Pineau, 86022 Poitiers Cedex, France
Cardiovasc Res 59:78-85. 2003..The present study aims to analyse the capacity of human atrial cardiac cells (i.e., cardiomyocytes and fibroblasts) to display the gp130 receptor subunit, and to evaluate its functionality...
- Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostateMar Royuela
Department of Cell Biology and Genetics, University of Alcala, Madrid, Spain
J Pathol 202:41-9. 2004..The role of OSM mainly in high Gleason grade carcinomas makes OSM a putative target for prostate cancer therapy...
- Enhancement of oligodendrocyte differentiation from murine embryonic stem cells by an activator of gp130 signalingPeilin Zhang
Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
Stem Cells 22:344-54. 2004..We conclude that this cytokine can significantly enhance the derivation of oligodendrocytes from ES cells...
- A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosisSouichi Yoshida
Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago 683 8504, Japan
Hum Reprod 19:1821-5. 2004..This study was undertaken to assess the effects of IL-6 and soluble IL-6 receptor (sIL-6R) on in vitro sperm motility...
- Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6Martin J Boulanger
Department of Microbiology and Immunology, Stanford University School of Medicine, Fairchild D319, 299 Campus Drive, Stanford, CA 94305 5124, USA
J Mol Biol 335:641-54. 2004..Viral IL-6 appears to utilize an elegant combination of both convergent, and unexpectedly divergent, molecular strategies to oligomerize gp130 and activate similar downstream signaling cascades as its human counterpart...
- The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signallingPatrick Fischer
Department of Biochemistry, Faculty of Medicine, RWTH Aachen, Pauwelsstrasse 30, D 52074 Aachen, Germany
Biochem J 378:449-60. 2004..Furthermore, cells lacking SOCS3 show constitutive STAT3 activation which is not affected by pre-stimulation with IL-6. All these observations suggest that desensitization and inhibition of signalling are mechanistically distinct...
- Reperfusion and Neurovascular Injury in StrokePak H Chan; Fiscal Year: 2013....
- Regulation of IL-6 mediated inflammation and tissue destruction by EGCGSalah Uddin Ahmed; Fiscal Year: 2013..Successful completion of this study will lay the foundation for testing EGCG as a treatment option for RA and other inflammatory diseases. ..
- Central Mechanisms of Orofacial PainJianren Mao; Fiscal Year: 2012..The outcome of this study could lead to the development of new therapeutic tools to treat often intractable and debilitating clinical orofacial pain. ..
- Characterizing Inflammation And Downstream Effects During Chronic Viral InfectionElina I Zuniga; Fiscal Year: 2012..Furthermore, since LCMV is considered a prototypic arenavirus the proposed studies will increase our understanding of the pathogenesis of human arenaviruses, which cause fatal hemorrhagic fevers. ..
- The Role of IL-6 Receptor in Irritant DermatitisRANDLE MICHAEL GALLUCCI; Fiscal Year: 2013..This research may also provide the rational for IL-6 based therapies that may find use in the prophylaxis or treatment of occupational dermatitis. ..
- ADAM17 in pancreatic cancer and pancreatitisHoward C Crawford; Fiscal Year: 2013....
- The role of IL-6 in jet fuel irritant dermatitisRANDLE MICHAEL GALLUCCI; Fiscal Year: 2010....
- Effects of IL-6 blockade in treated HIV infectionBenigno Rodriguez; Fiscal Year: 2013..We will examine the effects of IL-6 receptor blockade on the peripheral blood leukocyte transcriptome and plasma metabolome and relate these to functional assays of immune pathogenesis and cardiovascular risk. ..
- Genotypic Interactions in Brain Cancer HeterogeneityFrank B Furnari; Fiscal Year: 2013....
- Pain and Well-being in Older Women: The Roles of Activity and MotivationSuzanne C Segerstrom; Fiscal Year: 2013..The study will advance understanding of how a common, age-relevant experience - physical pain - affects EWB and physical health. ..
- Development of a Novel RA/Atherosclerosis Mouse ModelHARRIS R PERLMAN; Fiscal Year: 2013..We predict that amelioration of both diseases will correlate with a reduction in tissue macrophages. ..
- Translational Regulation of Gene Expression in Neonatal PMNsChristian Con Yost; Fiscal Year: 2010..Results of these experiments will provide new and important mechanistic insight into the pathogenesis of NEC, and may lead to improvements in the prevention and treatment of this common and often devastating disease of prematurity. ..
- Regulation of hemopoietic stem cell expansion by calciotrophic hormonesRoberto Pacifici; Fiscal Year: 2013..New data about the role of T lymphocytes in the mechanism by which estrogen and PTH regulate HSCs will increase the scope and the depth of osteoimmunology, a novel field of multidisciplinary research. ..
- Blocking of IL-6 function to prevent Pg mediated Th17 responseJAN S POTEMPA; Fiscal Year: 2013..Positive findings will establish the regulation of human Th17 cells by P. gingivalis adhesins and gingipains. Results of the present investigation will be useful in design of novel therapeutic targets. ..
- NMR approaches to STAT3 structural characterization and inhibitor designANDREW TAYANJANA NAMANJA; Fiscal Year: 2013..abstract_text> ..
- Small-Molecule Antibody Recruiting Therapeutics for Treating Human DiseaseDavid Spiegel; Fiscal Year: 2009..If successful, the proposed method would represent a novel therapeutic approach to a variety of human diseases. ..
- Cytokine control of Red Blood Cell AlloimmunizationCHANCE MARION JOHN LUCKEY; Fiscal Year: 2013..In the fullness of time, we anticipate that identification of the molecular circuitry driving RBC antibody production will provide therapeutic and diagnostic targets for further clinical development. ..
- INHIBITION OF IL-6 AND STAT3 IN RHEUMATOID ARTHRITISLionel Ivashkiv; Fiscal Year: 1999..3) Characterize the functional consequences of ERK-mediated inhibition of IL-6 signal transduction using the M1 myeloid cell differentiation system. ..
- Transplantation: Graft Cell Promotion of RejectionDavid Perkins; Fiscal Year: 2004..Aim 2 will identify cells in the peripheral lymphoid tissue with IL-6 dependent activation. And, Aim 3 will determine the mechanisms of IL-6 dependent activation of alloimmune responses by modulation of regulatory T cells. ..
- Normal and UV-Induced cutaneous antigen presenting cellsKevin Cooper; Fiscal Year: 2007..Aim III translates these findings in vivo to confirm their role in integrated immune response regulation, leading to novel immunotherapeutic strategies with clinical impact. ..
- Inflammatory factors, genes and stress induced pressure natriuresis in youthHaidong Zhu; Fiscal Year: 2007..Understanding the connections between stress, inflammation, and genes will provide a fresh approach into evaluating risk factors for high blood pressure. [unreadable] [unreadable] [unreadable]..
- Health Effects of Air Pollution in an Elderly PopulationJeffrey Sullivan; Fiscal Year: 2006..Elucidating molecular mechanisms of susceptibility to air pollution induced morbidity will aid in designing public health policy to prevent morbidity and mortality from air pollution. ..
- Integrin CD11b and its role in immune suppressionLi Zhang; Fiscal Year: 2010....
- IN VIVO REGULATION OF IL6 AND IL6R GENE EXPRESSIONCHARLES O BRIEN; Fiscal Year: 2002..Finally, cis-acting regulatory elements in the IL-6 promoter that are the targets for estrogen and PTH actions in vivo will be identified. ..
- ERBB KINASE ACTIVATION AND TRANSFORMATIONHsing Jien Kung; Fiscal Year: 2004..The present proposal is based on the above three novel findings and intends to study: 1) the mechanisms involved in receptor cross talk between erbB2 and IL6 receptor and 2) the NED signal pathways mediated by erbB2 and Etk. ..
- IL-6 & SIL-6R GROWTH INHIBITION OF BREAST CARCINOMANITA MAIHLE; Fiscal Year: 1999....
- Cell-targeting peptide nucleic acids for hormone-refractory prostate cancerBeverly Barton; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- role of adipokines in colon epithelial cell homeostasisJENIFER FENTON; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Skeletal muscle contractile dysfunction in heart failureMICHAEL TOTH; Fiscal Year: 2009..Our findings will also provide information regarding the utility of resistance exercise training to improve single muscle fiber function, as well as whole muscle performance and whole body physical function in heart failure patients. ..
- Role of IL-6 and estrogen in PTH-induced bone resorptionUrszula Masiukiewicz; Fiscal Year: 2003..3. Examine the molecular mechanism underlying PTH-induced increases in IL-6 production by bone cells and the modulating effect of estrogen on this process. ..
- Effects of ovarian suppression on substrate metabolismMICHAEL TOTH; Fiscal Year: 2007..Our findings will have direct relevance to understanding the fundamental role of ovarian hormone deficiency in the physiologic and metabolic changes that occur with menopause. ..
- SKELETAL MUSCLE PROTEIN METABOLISM IN HEART FAILUREMICHAEL TOTH; Fiscal Year: 2001..These experiments will provide new information regarding the pathophysiological mechanisms responsible for the loss of skeletal muscle protein quality and quantity in heart failure patients. ..
- SKELETAL MUSCLE PROTEIN METABOLISM IN HEART FAILUREMICHAEL TOTH; Fiscal Year: 2003..These experiments will provide new information regarding the pathophysiological mechanisms responsible for the loss of skeletal muscle mass and strength in heart failure patients. ..
- THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMENPaul Ridker; Fiscal Year: 2002....
- SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSISPaul Ridker; Fiscal Year: 2002....
- IL-6 AND ESTROGEN AND PTH INDUCED BONE RESORPTIONUrszula Masiukiewicz; Fiscal Year: 2002..3) We will study the molecular mechanism of the PTH-induced increase in IL-6 production by bone cells and the modulating effect of estrogen on this process. ..
- Phase II Trial of Thalidomide in Primary AmyloidosisAngela Dispenzieri; Fiscal Year: 2002..The ultimate goal of the proposed studies is to improve the prognosis of patient with this fatal disease. ..
- Oncostatin M and Leukemia Inhibitory Factor BiologyHeinz Baumann; Fiscal Year: 2004..Understanding the cell type-specific regulation of IL-6-type cytokine receptor activities will assist in designing treatments that will manipulate beneficial IL-6 cytokine effects during inflammation and tissue repair. ..
- CYTOKINE REGULATION OF MATURE MYELIN-SPECIFIC T CELLSBenjamin Segal; Fiscal Year: 2004..These studies may have therapeutic relevance to MS as well as provide insights into the pathways by which IL-12 regulates differentiated effector T cells. ..
- CELL ADHESION IN TISSUE MORPHOGENESISWilliam Carter; Fiscal Year: 2001..these results will define the molecular mechanism through which cell adhesion regulates gene expression and wound repair in epithelium. ..
- MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMADiane Jelinek; Fiscal Year: 2002....
- CELLULAR PHYSIOLOGY OF STAT3PRAVIN SEHGAL; Fiscal Year: 2002..Establishing the basic subunit structure of the cytosolic 200-400 kDa and 1-2 MDa STAT3-containing complexes in IL-6-free and IL-6-treated cells is a sine qua non for further progress in this field. ..
- DEVELOPMENT OF A NOVEL BIOARTIFICIAL LIVERJacek Rozga; Fiscal Year: 2002..S. lone to keep liver failure patients alive until an organ becomes available for transplantation or the native liver recovers from injury ($1.5-billion market). ..
- MITOGENIC SIGNALING BY ENDOTHELIN PEPTIDESMichael Simonson; Fiscal Year: 2002..Finally, whether rho is in the Src pathway or not, will be examined by cotransfection with constitutively active v-Src/dominant negative RhoA and vice versa and evaluation of c-fos induction/ DNA synthesis. ..
- AGING, GENE EXPRESSION AND OXIDATIVE STRESSEvan Keller; Fiscal Year: 2002....
- Lung epithelium-derived IL-6 in CD4+ T cell immune resp*Mercedes Rincon; Fiscal Year: 2004..abstract_text> ..
- VEGF and bone remodeling in skeletal metastasesEvan Keller; Fiscal Year: 2005..In this aim, we will test which VEGF isoform contributes to CaP cells' osteoblastic activity. We will also evaluate if VEGF induces this activity through MAPK. ..
- Cytokine Polymorphisms and Hodgkin Lymphoma RiskWendy Cozen; Fiscal Year: 2006..This study is important since it may will lead to identification of causal genetic factors which may offer alternative therapeutic strategies or prevention. ..
- Intimate Partner Violence and Inflammatory ProcessesTamara Newton; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Associating genetic variation to resistance to severe malaria in East AfricaDavid Reich; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Differential Gene Expression in the Cochlear NucleusDavid Friedland; Fiscal Year: 2008..These data will also provide a powerful template upon which to test and design novel treatments for improving hearing, discrimination and tinnitus in a significant portion of the population. ..
- Identification of an IL-6 induced keratinocyte motogenRANDLE GALLUCCI; Fiscal Year: 2008..The results of these experiments will hopefully lead to the eventual development of a useful treatment for chronic wounds. ..
- Gene-Environment Interactions in Obesity and DiabetesTracy Nelson; Fiscal Year: 2007..Environment: Dr. Nelson will have an outstanding environment in which to carry out the proposed study, as well as, the necessary resources and support to successfully complete her training. ..
- Monocyte / Macrophage TLR4 Expression and Signaling: A Link between Obesity and CBrian McFarlin; Fiscal Year: 2008..The primary purpose of this investigation is to determine if obesity status alters TLR4 signaling and/or inflammatory cytokine production in blood monocyte and adipose tissue macrophage. [unreadable] [unreadable] [unreadable]..
- Genetic Studies of Substance Abuse in Iowa AdopteesRobert Philibert; Fiscal Year: 2008..unreadable] [unreadable]..
- Advanced Training in Clinical InvestigationBruce Cronstein; Fiscal Year: 2008..We strongly believe that creation of this new program to prepare the next generation of clinician-investigators to bring the remarkable advances made at the bench to the patient. ..
- MECHANISMS OF AUTOREACTIVITY IN SLERobert Eisenberg; Fiscal Year: 2009..Such insights should be readily translatable to human autoimmune diseases. ..
- PLACENTAL FUNCTION IN PREECLAMPSIAYuping Wang; Fiscal Year: 2009..Results obtained from the proposed work should enhance our knowledge and establish a direct link of placental TC activity and EC dysfunction in PE. ..
- Gender differences in liver IL-6R expressionRANDLE GALLUCCI; Fiscal Year: 2007..By exposing ethanol- consuming rats to IL-6R agonists, it should be possible to correlate damage with receptor activation. [unreadable] [unreadable] [unreadable]..
- Raft/Caveolar Mechanisms in Pulmonary HypertensionPRAVIN SEHGAL; Fiscal Year: 2007..unreadable] [unreadable]..
- Pro & Anti-Inflammatory Cytokines in Colorectal CancerGLORIA YF HO; Fiscal Year: 2010..These high-risk individuals may benefit from prophylactic NSAIDS for prevention of colorectal cancer. ..
- PHARMACOLOGIC PROMOTION OF WOUND HEALINGBruce Cronstein; Fiscal Year: 2007..These studies should provide new insights into the mechanism by which adenosine A2A receptor agonists, a novel therapy undergoing clinical trials for wound healing of diabetic foot ulcers, promote wound healing. ..